Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous booster

Gian Luca Salvagno¹,², Brandon M. Henry³, Laura Pighi¹,², Simone De Nitto¹,², Giuseppe Lippi¹,

¹ Section of Clinical Biochemistry, University of Verona, Verona, Italy
² Service of Laboratory Medicine, Pederzoli Hospital, Peschiera del Garda, Italy
³ Clinical Laboratory, Division of Nephrology and Hypertension, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA

ARTICLE INFO

Corresponding authors:
Prof. Giuseppe Lippi
Section of Clinical Biochemistry
University Hospital of Verona
Piazzale L.A. Scuro, 10
37134 Verona
Italy
Phone: 0039-045-8122970
Fax: 0039-045-8124308
E-mail: giuseppe.lippi@univr.it

Key words:
COVID-19, SARS-CoV-2, vaccination, antibodies, immune response

ABSTRACT

Background
In this serosurveillance study, we investigated the variation of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in healthcare workers receiving primary BNT162b2 vaccination and homologous booster.

Methods
A total number of 524 subjects (median age, 46 years; 65.3% females), were studied. All received primary BNT162b2 vaccination (two doses) and homologous booster (one dose) >8 months after completing the primary cycle. Blood samples were collected before the first and second vaccine doses, at 1, 3 and 6 months after the second dose, as well as before and 1 month after booster. Total anti-SARS-CoV-2 neutralizing anti-
Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous booster

Results
Overall, 65.1% subjects were baseline (i.e., pre-vaccination) SARS-CoV-2 seronegative and always tested SARS-CoV-2 negative (“N/N”), 16.2% were baseline SARS-CoV-2 seronegative but tested SARS-CoV-2 positive after receiving the vaccine booster dose (“N/P”), whilst 18.7% were baseline SARS-CoV-2 seropositive and always tested SARS-CoV-2 negative afterwards (“P/N”). All groups displayed a similar trend of total anti-SARS-CoV-2 S antibodies throughout the study period, though the P/N cohort exhibited higher values compared to the other two groups until receiving the booster, after which the levels become similar in all cohorts. Significant differences in total anti-SARS-CoV-2 S antibodies values were not found between N/N and N/P groups, neither 1 month after booster. The rate of subjects with protective antibodies values become 100% in all groups after booster.

Conclusions
Although baseline seropositivity is associated with more pronounced humoral immune response following primary vaccination compared to never infected subjects, SARS-CoV-2 infection after booster does not significantly foster antibody titers.

INTRODUCTION
Several lines of evidence now attest that no existing vaccine would be completely effective against an infectious diseases, thus including those that have been developed against coronavirus disease 2019 (COVID-19) [1]. For viruses like SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), global herd immunity is unlikely to be achieved for a variety of reasons that include lower than advisable compliance to vaccination [2], progressive accumulation of non-synonymous genomic mutations that promote escape from vaccine-elicited immunity [3], as well as waning vaccine efficacy and protection over time, which is mostly attributable to a decline in the titer of anti-SARS-CoV-2 neutralizing antibodies [4,5]. To this end, epidemiological and laboratory investigations are needed to precisely recognize and measure the impact of the many determinants that may contribute to impair vaccine efficacy over time, thus allowing for the establishment of timely and appropriate measures that could be effective to limit SARS-CoV-2 circulation, prevent or reduce the risk of developing severe COVID-19 illness, and limit emergence of novel variants [6].

In a world with limited resources, where vaccine coverage remains extremely heterogeneous across different countries and populations mostly for insufficient supply [7], prioritization of primary vaccination and booster doses administration to those parts of the population that may be more exposed to complications and adverse consequences of SARS-CoV-2 infection is crucial [8]. Among the potentially more vulnerable subjects, those with blunted immunogenic response and sharper and/or faster decay of anti-SARS-CoV-2 neutralizing antibodies were found to have magnified risk of breakthrough infections and unfavorable progression of COVID-19, including increased rates of hospital admission, need of mechanical ventilation or intensive care, and a greater risk of death [9,10]. Personalized vaccine administration would also be effective to concomitantly avert the risk of rare side effects in those who could safely delay primary cycle or boosters [11].

Since the extent of vaccine-elicited protection varies considerably when combined with SARS-CoV-2 infections [12], this serosurveillance study was aimed to explore the variation of total anti-
SARS-CoV-2 antibodies in healthcare workers receiving primary vaccination with BNT162b2 and homologous booster, with or without SARS-CoV-2 infection before primary vaccination or after vaccine booster.

MATERIALS AND METHODS

The initial study population consisted of 925 ostensibly healthy individuals recruited from the healthcare staff of the Pederzoli Hospital in Peschiera del Garda (Italy), who received a primary vaccination cycle with BNT162b2 COVID-19 vaccine (Pfizer Inc., New York, NY; two doses of 30 µg, separated by 3 weeks), and an additional homologous booster (a single dose of 30 µg) more than 8 months after completing the primary vaccination. BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine encoding a pre-fusion, stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. A nucleic acid amplification test (NAAT) for diagnosing incident SARS-CoV-2 infection was performed every 2-4 weeks throughout the study period, using Altona Diagnostics RealStar SARS-CoV-2 RT-PCR Kit (Altona Diagnostics GmbH, Hamburg, Germany) or Seegene Allplex SARS-CoV-2 Assay (Seegene Inc., South Korea). Venous blood was collected before administration of the first (baseline) and second BNT162b2 doses, then 1, 3 and 6 months after the second BNT162b2 dose, and finally immediately before and 1 month after the homologous BNT162b2 booster dose. Subjects who became SARS-CoV-2 positive between the first dose of vaccine and the booster were actually excluded from our analysis. This is due to the fact that the time passed between these vaccine doses was so long that the influence of a SARS-CoV-2 infection on humoral immunity throughout nearly 8 months could not be standardized.

Total anti-SARS-CoV-2 neutralizing antibodies were assayed using the Roche Elecsys Anti-SARS-CoV-2 S chemiluminescent immunoassay, on a Roche Cobas 6000 immunochemistry platform (Roche Diagnostics, Basel, Switzerland). This double-antigen sandwich method encompasses a recombinant form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein, displays total imprecision <4% [13], as well as optimal agreement with plaque reduction neutralization test (PRNT) in vaccinated subjects (area under the curve, 0.990; sensitivity, 0.98; specificity, 0.95) [14]. According to manufacturer’s specifications, results are positive when the serum total anti-SARS-CoV-2 antibodies concentration is ≥0.8 kBAU/L (kilo binding antibody units/L). A total anti-SARS-CoV-2 antibodies titer of 656 kBAU/L was considered as predictive of ≥80% protection against modest or severe COVID-19 illness, in keeping with previously published data [15,16].

Results of testing were finally reported as median and interquartile range (IQR), and the statistical analysis was performed using Analyse-it (Analyse-it Software Ltd, Leeds, UK). Between-group comparisons were carried out with Mann-Whitney test. All participants gave informed consents for vaccination and undergoing serial anti-SARS-CoV-2 antibodies testing. This observational study was reviewed and cleared by the Ethics Committee of Verona and Rovigo provinces (3246CESC), and was conducted in accordance with the Declaration of Helsinki, under the terms of relevant local legislation.

RESULTS

The final study population consisted of 524 subjects (median age, 46 years and IQR, 34-53 years; 65.3% females; 56.6% of the original sample), as 401 subjects were lost on follow-up (for either not completing vaccination, failing to provide blood samples at one or more time point throughout the study). Eleven additional subjects tested positive for SARS-CoV-2 mRNA
after the first and before the third vaccine dose, but were also excluded due to the insufficient sample size to enable analysis of this subgroup. Of all subjects finally included, 341/524 (65.1%) were baseline (i.e. pre-vaccination) SARS-CoV-2 seronegative (i.e., <0.8 kBAU/L) and then always tested SARS-CoV-2 negative (“N/N”; median age, 47 years and IQR, 36-54 years; 63.9% females); 85/524 (16.2%) were baseline SARS-CoV-2 seronegative (i.e., <0.8 kBAU/L) and then tested SARS-CoV-2 positive after receiving the vaccine booster dose (“N/P”; median age, 43 years and IQR 31-50 years; 68.2% females); whilst 98/524 (18.7%) were baseline SARS-CoV-2 seropositive (i.e., >0.8 kBAU/L) and then always tested SARS-CoV-2 negative (“P/N”; median age, 44 years and IQR, 33-52 years; 67.3% females), respectively. We excluded the cohort of subjects who were baseline SARS-CoV-2 seropositive (i.e., >0.8 kBAU/L) and then tested SARS-CoV-2 positive after receiving the vaccine booster dose always tested (i.e., P/P) because the final sample size of this cohort was considerably low (n=9), so that inclusion in the statistical analysis may be misleading. Subjects in the N/N cohort were slightly younger than those in the two other groups (i.e., p=0.035 vs. N/P and p=0.039 vs. P/N, respectively), whilst the sex distribution was similar across the three groups (all p>0.05).

The main variations of total anti-SARS-CoV-2 S antibodies in the three groups are summarized in table 1 and figure 1. As predicted, although all groups displayed a rather similar trend throughout the study period, the P/N cohort exhibited significantly higher values compared to the other two groups until these subjects received the vaccine booster dose, after which the serum antibodies levels become comparable to those of the other two cohorts. No significant differences were observed between the N/N and N/P groups, including at the 1 month time point after receiving the vaccine booster dose (Table 1).

The rate of subjects with protective total serum anti-SARS-CoV-2 S antibodies values (i.e., >656 kBAU/L) displayed rather consistent trend across groups. Specifically, in N/N and N/P the rate of positive subjects increased from 0% to 82-84% 1 months after the second vaccine dose, but then gradually declined to 32-35% before receiving the vaccine booster, after which such rate increased in both groups to 100% (Figure 2). Unlike these subjects though, the rate of P/N subjects with protective total anti-SARS-CoV-2 S antibodies values was 7% at baseline assessment, then remained always >88% throughout the subsequent time points, and increased further to 100% after receiving the vaccine booster dose.

**DISCUSSION**

Some important conclusions can be made from the results of this serosurveillance study in a group of healthcare workers who received a primary BNT162b2 vaccination followed by a homologous booster.

The first important aspect, which supports previously published evidence [17-19], is that a prior SARS-CoV-2 infection before primary vaccination provides a rather efficient priming to COVID-19 vaccination, in that the total anti-SARS-CoV-2 S antibodies values appear to be consistently higher in baseline seropositive individuals (P/N) compared to seronegative ones (both N/N and N/P groups in our study). The protection against the risk of developing moderate/severe COVID-19 illness (i.e., the subjects with predictably protective antibodies values) seems also to persist for longer after primary vaccination in baseline seropositive compared to baseline seronegative subjects (i.e., 88% in P/N vs. 32-35% in N/N and N/P, respectively), which would allow to safely prioritize the administration of vaccine boosters to seronegative individuals.

The second important aspect that emerged from this serosurveillance study, is that the vaccine
booster dose generates a considerable impact on total anti-SARS-CoV-2 S antibodies, increasing their concentration by around 50- and 8-fold in seronegative and seropositive subjects, respectively, though the final values reached do not significantly differ among all groups (Table 1). This is basically consistent with two, non-mutually exclusive, hypotheses. It can be first conjectured that the priming effect of a pre-vaccination SARS-CoV-2 infection has progressively declined over time, being almost completely lost before receiving the vaccine booster dose, such that baseline SARS-CoV-2 seronegative and seropositive subjects would become a more homogenous population. This is not really surprising, since total anti-SARS-CoV-2 antibodies display a half-life between 50-110 days [20], with a seropositive rate decreasing to less than 36% after 12 months [21].

Table 1: Serum concentration (median and interquartile range) of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers receiving primary BNT162b2 vaccination and homologous booster

| Population | Baseline | Pre-2nd dose | 1 M after 2nd dose | 3 M after 2nd dose | 6 M after 2nd dose | Pre-booster | 1 M post-booster |
|------------|----------|-------------|-------------------|-------------------|------------------|-------------|----------------|
| **SARS-CoV-2 N/N** | | | | | | | |
| Values (kBAU/L) | <0.8 | 42.8 (15.4-96.1) | 1440.0 (854.5-2269.0) | 936.4 (601.2-1464.0) | 661.6 (407.7-1023.0) | 429.8 (265.8-744.0) | 20848.0 (13218.0-25000.0) |
| **SARS-CoV-2 N/P** | | | | | | | |
| Values (kBAU/L) | <0.8 | 39.6 (14.1-87.4) | 1289.0 (770.8-2011.0) | 902.9 (517.4-1538.0) | 656.0 (380.5-1088.0) | 452.5 (244.0-911.8) | 20891.0 (14028.0-25000.0) |
| p vs. N/N | 1.000 | 0.258 | 0.510 | 0.321 | 0.180 | 0.110 | 0.392 |
| **SARS-CoV-2 P/N** | | | | | | | |
| Values (kBAU/L) | 80.8 (31.1-209.8) | 13312.0 (5198.3-25000.0) | 16358.0 (6898.8-25000.0) | 6673.5 (2525.8-14395.0) | 3529.5 (1523.0-8664.3) | 2366.0 (1150.5-5777.8) | 19290.0 (13720.5-25000.0) |
| p vs. N/N | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| p vs. N/P | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.364 |

N/N, baseline SARS-CoV-2 seronegative and then always testing SARS-CoV-2 negative; N/P, baseline SARS-CoV-2 seronegative and testing SARS-CoV-2 positive after booster; P/N, baseline SARS-CoV-2 seropositive and then always testing SARS-CoV-2 negative; M, months; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Figure 1
Serum concentration (median and interquartile range) of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies in a cohort of healthcare workers receiving primary BNT162b2 vaccination and homologous booster. The white arrows indicate the timing of BNT162b2 vaccine doses, whilst the gray arrow indicates the SARS-CoV infection in the N/P group.

N/N, baseline SARS-CoV-2 seronegative and then always testing SARS-CoV-2 negative; N/P, baseline SARS-CoV-2 seronegative and testing SARS-CoV-2 positive after booster; P/N, baseline SARS-CoV-2 seropositive and then always testing SARS-CoV-2 negative; M, months; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Gian Luca Salvagno, Brandon M. Henry, Laura Pighi, Simone De Nitto, Giuseppe Lippi
Variation of total anti-SARS-CoV-2 antibodies after primary BNT162b2 vaccination and homologous booster

Figure 2  Rate of subjects with protective levels of total anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) antibodies (i.e., >656 kBAU/L) in a cohort of healthcare workers receiving primary BNT162b2 vaccination and homologous booster.

N/N, baseline SARS-CoV-2 seronegative and then always testing SARS-CoV-2 negative; N/P, baseline SARS-CoV-2 seronegative and testing SARS-CoV-2 positive after booster; P/N, baseline SARS-CoV-2 seropositive and then always testing SARS-CoV-2 negative; M, months; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
On the other hand, it is also conceivable that the administration of a BNT162b2 booster dose has provided such a strong stimulus to an already primed immunological memory (i.e., memory B cells) [22], such that another potent immunogenic trigger like an incident SARS-CoV-2 infection occurred after vaccine booster would be incapable to produce further significant increases of total anti-SARS-CoV-2 S antibodies levels over the threshold achieved with vaccine boosters.

Research funding: None declared.

Author contributions
All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Informed consent
Informed consent was obtained from all individuals included in this study.

Ethical approval
This observational study was reviewed and cleared by the Ethics Committee of Verona and Rovigo provinces (3246CESC).

Conflict of interest statement
All the authors declare that they have no conflict of interest in this work.

Acknowledgments
The authors acknowledge the staff of the Service of Laboratory Medicine of the Pederzoli Hospital (Peschiera del Garda, Italy) for the skill technical assistance.

REFERENCES
1. Monto AS. The Future of SARS-CoV-2 Vaccination - Lessons from Influenza. N Engl J Med 2021;385:1825-1827.
2. Burki T. The online anti-vaccine movement in the age of COVID-19. Lancet Digit Health 2020;2:e504-505.
3. Lippi G, Mattiuzzi C, Henry BM. Updated picture of SARS-CoV-2 variants and mutations. Diagnosis (Berl) 2021;9:11-17.
4. Notarte KI, Guerrero-Arguero I, Velasco JV, Ver AT, Santos de Oliveira MH, Catahay JA, et al. Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. J Med Virol. 2022 Feb 28. doi: 10.1002/jmv.27688. Epub ahead of print.
5. Bonnet B, Chabrolles H, Archimbaud C, Brebion A, Cosme J, Dutheil F, et al. Decline of Humoral and Cellular Immune Responses Against SARS-CoV-2 6 Months After Full BNT162b2 Vaccination in Hospital Healthcare Workers. Front Immunol 2022;13:842912.
6. Dolgin E. COVID vaccine immunity is waning - how much does that matter? Nature 2021;597:606-607.
7. Hassan F, London L, Gonsalves G. Unequal global vaccine coverage is at the heart of the current covid-19 crisis. BMJ. 2021 Dec 13;375:n3074.
8. Lee I, Tipoe E. Global COVID-19 vaccine inequity: Preferences for overseas vaccine donations over booster shots. Brain Behav Immun Health 2022;21:100447.
9. Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-2040.
10. Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 2022;375:43-50.
11. Singh A, Nguyen L, Everest S, Afzal S, Shim A. Acute Pericarditis Post mRNA-1273 COVID Vaccine Booster. Curreo 2022;14:e22148.
12. Milne G, Hames T, Scotton C, Gent N, Johnsen A, Anderson RM, et al. Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity? Lancet Respir Med 2021;9:1450-1466.
13. Higgins V, Fabros A, Kulasingam V. Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation. J Clin Microbiol 2021;59:e03149-20.
14. Padoan A, Cosma C, Bonfante F, Rocca FD, Barbaro F, Santarossa C, et al. SARS-CoV-2 neutralizing antibodies after one or two doses of Comirnaty (BNT162b2, BioNTech/Pfizer): Kinetics and comparison with chemiluminescent assays. Clin Chim Acta 2021;523:446-453.
15. Maier HE, Balmaseda A, Ojeda S, Cerpas C, Sanchez N, Plazaola M, et al. An immune correlate of SARS-CoV-2 infection and severity of reinfections. medRxiv [Preprint]. 2021 Nov 24:2021.11.23.21266767. doi: 10.1101/2021.11.23.21266767.

16. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033-1036.

17. Salvagno GL, Henry BM, di Piazza G, Pighi L, De Nitto S, Bragantini D, et al. Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Sero-negative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination. Diagnostics (Basel) 2021;11:832.

18. Urlaub D, Wolfsdorff N, Durak D, Renken F, Watzl C. SARS-CoV-2 infection shortly after BNT162b2 vaccination results in high anti-spike antibody levels in nursing home residents and staff. Immun Inflamm Dis 2021;9:1702-1706.

19. Ali H, Alahmad B, Al-Shammari AA, Alterki A, Hammad M, Cherian P, et al. Previous COVID-19 Infection and Antibody Levels After Vaccination. Front Public Health 2021;9:778243.

20. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 2020;5:eabe0367.

21. Pelleau S, Woudenberg T, Rosado J, Donnadieu F, Garcia L, Obadia T, et al. Kinetics of the Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and Serological Estimation of Time Since Infection. J Infect Dis 2021;224:1489-1499.

22. Goel RR, Apostolidis SA, Painter MM, Mathew D, Pattekar A, Kuthuru O, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination. Sci Immunol 2021;6:eabi6950.